Lu 35-138

Lu 35-138 is a dual dopamine D 4 receptor antagonist and serotonin reuptake inhibitor (SRI) among other actions which belongs to the tetrahydropyridinylindole group and was under development for the treatment of schizophrenia but was never…

Uses your system voice; voice and rate in settings.

Snapshot

≈ 4 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Lu 35-138 is a dual dopamine D 4 receptor antagonist and serotonin reuptake inhibitor (SRI) among other actions which belongs to the tetrahydropyridinylindole group and was under development for the treatment of schizophrenia but was never marketed. Its route of administration is unspecified.

The drug shows high affinity for the dopamine D 4 receptor (K i = 5 nM) and is a competitive antagonist of this receptor (K b = 8 nM). In addition, it is a potent serotonin reuptake inhibitor, with an of 3.2 nM.

Subsequent research found that Lu 35-138 is a potent negative allosteric modulator or allosteric inhibitor of the serotonin transporter (SERT), with an of 43.8 nM in the later study. Lu 35-138 also shows affinity for the α 1 -adrenergic receptor (K i = 45 nM).

Its affinities for various other monoamine receptors have been reported as well, for instance at the dopamine D 2 receptor (K i = 72 nM; 14.4-fold lower than for the dopamine D 4 receptor) and serotonin 5-HT 2A receptor (K i = 260 nM), with significant dopamine D 2 receptor occupancy notably observed in vivo in rodents. In addition to its actions at monoaminergic targets, Lu 35-138 is a hERG blocker, with an of 270 nM.

For comparison, haloperidol and sertindole had values for this action of 170 nM and 64 nM, respectively.…

Lu 35-138 is a dual dopamine D 4 receptor antagonist and serotonin reuptake inhibitor (SRI) among other actions which belongs to the tetrahydropyridinylindole group and was under development for the treatment of schizophrenia but was never marketed. Its route of administration is unspecified.

The drug shows high affinity for the dopamine D 4 receptor (K i = 5 nM) and is a competitive antagonist of this receptor (K b = 8 nM). In addition, it is a potent serotonin reuptake inhibitor, with an of 3.2 nM.

Subsequent research found that Lu 35-138 is a potent negative allosteric modulator or allosteric inhibitor of the serotonin transporter (SERT), with an of 43.8 nM in the later study. Lu 35-138 also shows affinity for the α 1 -adrenergic receptor (K i = 45 nM).

Its affinities for various other monoamine receptors have been reported as well, for instance at the dopamine D 2 receptor (K i = 72 nM; 14.4-fold lower than for the dopamine D 4 receptor) and serotonin 5-HT 2A receptor (K i = 260 nM), with significant dopamine D 2 receptor occupancy notably observed in vivo in rodents. In addition to its actions at monoaminergic targets, Lu 35-138 is a hERG blocker, with an of 270 nM.

For comparison, haloperidol and sertindole had values for this action of 170 nM and 64 nM, respectively. Similarly to many antidepressants, Lu 35-138 produces antiaggressive effects acutely and proaggressive effects with chronic administration in rodents. It reverses the hyperlocomotion induced by dextroamphetamine and phencyclidine (PCP) in rodents.

However, it was unable to affect the hyperlocomotion induced by a high dose of dextroamphetamine, which was said to reflect a preferential action on limbic versus striatal structures. The drug also reduced dextroamphetamine-induced disruption of prepulse inhibition.

Continuous administration of Lu 35-138 reduced the number of spontaneously active dopaminergic neurons in the ventral tegmental area (VTA), which was said to be consistent with antipsychotic-like activity. Lu 35-138 did not produce catalepsy in rodents or dystonia in monkeys, suggesting low risk of extrapyramidal symptoms (EPS).

Due to unfavorable physicochemical properties, the drug has been found to have very low oral bioavailability of less than 5% in rats. Lu 35-138 was first described in the scientific literature by 2002. It was under development by Lundbeck in Denmark.

The drug reached phase 2 clinical trials for schizophrenia prior to the discontinuation of its development in December 2003.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1378559950 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.